Clinical Trials
22 trialsNCT04008797 2026-03-24
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT02853500 2025-02-05
Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies
Dana-Farber Cancer Institute
Phase 4 Withdrawn
NCT00003907 2023-07-05
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00956930 2022-11-21
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
Northwestern University
Phase 2 Completed
NCT01464593 2022-10-13
ABLATE
Imunon
Phase 2 Terminated
NCT01011010 2018-01-05
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00047229 2017-11-08
Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
University Health Network, Toronto
Phase 2 Completed
NCT02958163 2017-11-07
HepSTAR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT00524316 2017-05-09
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01009801 2015-07-07
Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
Swiss Cancer Institute
Phase 1/2 Terminated
NCT00108953 2014-10-31
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00077389 2014-06-24
Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00079027 2013-12-18
Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00003912 2013-12-04
Chemotherapy in Treating Children With Liver Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00276705 2013-09-17
Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002608 2013-07-10
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00012324 2013-06-26
Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01858207 2013-05-23
Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
Chang Gung Memorial Hospital
Phase 2 Unknown
NCT01042041 2013-02-26
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00471484 2011-06-22
Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004248 2011-03-07
Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Completed
NCT00006198 2005-06-24
Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer
National Center for Research Resources (NCRR)
Phase 2 Unknown